Advertisement

A Cannabinoid Receptor-Mediated Mechanism Participates in the Neuroprotective Effects of Oleamide Against Excitotoxic Damage in Rat Brain Synaptosomes and Cortical Slices

  • Marisol Maya-López
  • Leonardo C. Rubio-López
  • Ivana V. Rodríguez-Alvarez
  • Julián Orduño-Piceno
  • Yuliza Flores-Valdivia
  • Aline Colonnello
  • Edgar Rangel-López
  • Isaac Túnez
  • Oscar Prospéro-García
  • Abel SantamaríaEmail author
Original Article
  • 4 Downloads

Abstract

A number of physiological responses in the central nervous system (CNS) are regulated by the endocannabinoid system (ECS). Inhibition of neuronal excitability via activation of cannabinoid receptors (CBr) constitutes a potential protective response against neurotoxic insults. Oleamide (ODA) is a fatty acid amide with endocannabinoid profile exerting several effects in the CNS, though its neuroprotective properties remain unknown. The tryptophan metabolite quinolinic acid (QUIN) elicits toxic effects via overactivation of N-methyl-d-aspartate receptors (NMDAr) after its accumulation in the CNS under pathological conditions. Here, we investigated the protective properties of ODA against the excitotoxic damage induced by QUIN in rat brain synaptosomes and cortical slices, and whether these effects are linked to the stimulation of the endocannabinoid system via CB1 and/or CB2 receptor activation. ODA (1–50 μM) prevented the QUIN (100 μM)-induced loss of mitochondrial reductive capacity in synaptosomes in a mechanism partially mediated by CB1 receptor, as evidenced by the recovery of mitochondrial dysfunction induced by co-incubation with the CB1 receptor antagonist/inverse agonist AM281 (1 μM). In cortical slices, ODA prevented the short-term QUIN-induced loss of cell viability and the cell damage in a partial CB1 and CB2 receptor-dependent manner. Altogether, these findings demonstrate the neuroprotective and modulatory properties of ODA in biological brain preparations exposed to excitotoxic insults and the partial role that the stimulation of CB1 and CB2 receptors exerts in these effects.

Keywords

Excitotoxicity Endocannabinoid system Neuroprotection Oleamide Quinolinic acid Cannabinoid receptors 

Notes

Acknowledgments

The authors wish to express gratitude to Dr. Edith Monroy for her assistance for language improvement.

Funding Information

This work was supported by CONACYT-TUBITAK grants 265991 (CONACYT/SRE given to AS) and IN215218 (DGAPA-PAPIIT-UNAM given to OPG).

Compliance with Ethical Standards

The experimental protocols were approved by the Ethics Committee for Animal Research of the Instituto Nacional de Neurología y Neurocirugía (Project No. 126/17).

Conflict of Interest

The authors declare that they have no competing interests.

References

  1. Aguilera G, Colín-González AL, Rangel-López E, Chavarría A, Santamaría A (2018) Redox signaling, neuroinflammation, and neurodegeneration. Antioxid Redox Signal 28:1626–1651CrossRefGoogle Scholar
  2. Aguilera-Portillo G, Rangel-López E, Villeda-Hernández J, Chavarría A, Castellanos P, Elmazoglu Z, Karasu Ç, Túnez I, Pedraza G, Königsberg M, Santamaría A (2019) The pharmacological inhibition of fatty acid amide hydrolase prevents excitotoxic damage in the rat striatum: possible involvement of CB1 receptors regulation. Mol Neurobiol 56:844–856CrossRefGoogle Scholar
  3. Akanmu MA, Adeosun SO, Ilesanmi OR (2007) Neuropharmacological effects of oleamide in male and female mice. Behav Brain Res 182:88–94CrossRefGoogle Scholar
  4. Ano Y, Ozawa M, Kutsukake T, Sugiyama S, Uchida K, Yoshida A, Nakayama H (2015) Preventive effects of a fermented dairy product against Alzheimer’s disease and identification of a novel oleamide with enhanced microglial phagocytosis and anti-inflammatory activity. PLoS One 10:e0118512CrossRefGoogle Scholar
  5. Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutiérrez S, Martín-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, López-Rodríguez ML, Grandes P, Rossignol R, Marsicano G (2012) Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci 15:558–566CrossRefGoogle Scholar
  6. Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB (1998) Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci U S A 95:4810–4815CrossRefGoogle Scholar
  7. Boger DL, Fecik RA, Patterson JE, Miyauchi H, Patricelli MP, Cravatt BF (2000) Fatty acid amide hydrolase substrate specificity. Bioorg Med Chem Lett 10:2613–2616CrossRefGoogle Scholar
  8. Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, Fernández-Ruiz J, Galve-Roperh I, Guzmán M (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A 111:8257–8262CrossRefGoogle Scholar
  9. Coke CJ, Scarlett KA, Chetram MA, Jones KJ, Sandifer BJ, Davis AS, Marcus AI, Hinton CV (2016) Simultaneous activation of induced heterodimerization between CXCR4 chemokine receptor and cannabinoid receptor 2 (CB2) reveals a mechanism for regulation of tumor progression. J Biol Chem 291:9991–10005CrossRefGoogle Scholar
  10. Colín-González AL, Luna-López A, Königsberg M, Ali SF, Pedraza-Chaverrí J, Santamaría A (2014) Early modulation of the transcription factor Nrf2 in rodent striatal slices by quinolinic acid, a toxic metabolite of the kynurenine pathway. Neuroscience 260:130–139CrossRefGoogle Scholar
  11. Colín-González AL, Paz-Loyola AL, Serratos I, Seminotti B, Ribeiro CA, Leipnitz G, Souza DO, Wajner M, Santamaria A (2015) Toxic synergism between quinolinic acid and organic acids accumulating in glutaric acidemia type I and in disorders of propionate metabolism in rat brain synaptosomes: relevance for metabolic acidemias. Neuroscience 308:64–74CrossRefGoogle Scholar
  12. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506–1509CrossRefGoogle Scholar
  13. Dougalis A, Lees G, Ganellin CR (2004) The sleep lipid oleamide may represent an endogenous anticonvulsant: an in vitro comparative study in the 4-aminopyridine rat brain-slice model. Neuropharmacology 46:541–554CrossRefGoogle Scholar
  14. Fowler CJ (2004) Oleamide: a member of the endocannabinoid family? Br J Pharmacol 141:195–196CrossRefGoogle Scholar
  15. García-Morales V, Montero F, Moreno-López B (2014) Cannabinoid agonists rearrange synaptic vesicles at excitatory synapses and depress motoneuron activity in vivo. Neuropharmacology 92:69–79CrossRefGoogle Scholar
  16. Gobbi M, Mennini T, Valle FD, Cervo L, Salmona M, Diomede L (1999) Oleamide-mediated sleep induction does not depend on perturbation of membrane homeoviscosity. FEBS Lett 463:281–284CrossRefGoogle Scholar
  17. Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, Williamson KS (2006) On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 8:2075–2087CrossRefGoogle Scholar
  18. Huitrón-Resendiz S, Gombart L, Cravatt BF, Henriksen SJ (2001) Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp Neurol 172:235–243CrossRefGoogle Scholar
  19. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100:1375–1386CrossRefGoogle Scholar
  20. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296:420–425Google Scholar
  21. Kita M, Ano Y, Inoue A, Aoki J (2019) Identification of P2Y receptors involved in oleamide-suppressing inflammatory responses in murine microglia and human dendritic cells. Sci Rep 9:3135CrossRefGoogle Scholar
  22. Kotlar I, Rangel-López E, Colonnello A, Aguilera-Portillo G, Serratos IN, Galván-Arzate S, Pedraza-Chaverri J, Túnez I, Wajner M, Santamaría A (2019) Anandamide reduces the toxic synergism exerted by quinolinic acid and glutaric acid in rat brain neuronal cells. Neuroscience 401:84–95CrossRefGoogle Scholar
  23. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A (1999) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci 1:E4CrossRefGoogle Scholar
  24. Lee Y-J, Chung DY, Lee S-J, Jhon GJ, Lee Y-S (2006) Enhanced radiosensitization of P53 mutant cells by oleamide. Int J Radiat Oncol Biol Phys 64:1466–1474CrossRefGoogle Scholar
  25. Leggett JD, Aspley S, Beckett SR, D’Antona AM, Kendall DA, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253–262CrossRefGoogle Scholar
  26. Li Q, Yan H, Wilson WA, Swartzwelder HS (2010) Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. Brain Res 1342:127–137CrossRefGoogle Scholar
  27. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302:73–79CrossRefGoogle Scholar
  28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  29. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S (1999) Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer’s and Parkinson’s diseases. Ann N Y Acad Sci 893:154–175CrossRefGoogle Scholar
  30. Mechoulam R, Fride E, Hanu L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z (1997) Anandamide may mediate sleep induction. Nature 389:25–26CrossRefGoogle Scholar
  31. Mueller GP, Driscoll WJ (2009) Biosynthesis of oleamide. Vitam Horm 81:55–78CrossRefGoogle Scholar
  32. Muhl H, Pfeilschifter J (2003) Endothelial nitric oxide synthase: a determinant of TNFalpha production by human monocytes/macrophages. Biochem Biophys Res Commun 310:677–680CrossRefGoogle Scholar
  33. Murillo-Rodríguez E, Giordano M, Cabeza R, Henriksen SJ, Méndez Díaz M, Navarro L, Prospéro-García O (2001) Oleamide modulates memory in rats. Neurosci Lett 313:61.64CrossRefGoogle Scholar
  34. Nam HY, Na EJ, Lee E, Kwon Y, Kim HJ (2017) Antiepileptic and neuroprotective effects of oleamide in rat striatum on kainate-induced behavioral seizure and excitotoxic damage via calpain inhibition. Front Pharmacol 8:817CrossRefGoogle Scholar
  35. Nazari M, Komaki A, Karamian R, Shahidi S, Sarihi A, Asadbegi M (2016) The interactive role of CB1 and GABA B receptors in hippocampal synaptic plasticity in rats. Brain Res Bull 120:123–130CrossRefGoogle Scholar
  36. O’Sullivan S (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152:576–582CrossRefGoogle Scholar
  37. O’Sullivan S (2016) An update on PPAR activation by cannabinoids. Br J Pharmacol 12:1899–1910CrossRefGoogle Scholar
  38. Oh YT, Lee JY, Lee J, Lee JH, Kim J-E, Ha J, Kang I (2010) Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-κB activation in BV2 murine microglial cells. Neurosci Lett 474:148–153CrossRefGoogle Scholar
  39. Ortega A, Rangel-López E, Hidalgo-Miranda A, Morales A, Ruiz-García E, Meneses-García A, Herrera-Gómez A, Aguilar-Ponce JL, González-Herrera IG, Guevara-Salazar P, Prospero-García O, Del Angel SA (2015) On the effects of CP 55-940 and other cannabinoid receptor agonists in C6 and U373 cell lines. Toxicol in Vitro 29:1941–1951CrossRefGoogle Scholar
  40. Pascual AC, Gaveglio VL, Giusto NM, Pasquaré SJ (2014) Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. Exp Gerontol 55:134–142CrossRefGoogle Scholar
  41. Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A (2012) Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5:1–8Google Scholar
  42. Rangel-López E, Colín-González AL, Paz-Loyola AL, Pinzón E, Torres I, Serratos IN, Castellanos P, Wajner M, Souza DO, Santamaría A (2015) Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain. Neuroscience 285:97–106CrossRefGoogle Scholar
  43. Ribeiro CAJ, Grando V, Dutra Filho CS, Wannmacher CM, Wajner M (2006) Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 99:1531–1542CrossRefGoogle Scholar
  44. Robson PJ (2014) Therapeutic potential of cannabinoid medicines. Drug Test Analysis 6:24–30CrossRefGoogle Scholar
  45. Rodríguez-Muñoz M, Sánchez-Blázquez P, Merlos M, Garzón Niño J (2016) Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget 34:55840–55862Google Scholar
  46. Sánchez-Blázquez P, Rodríguez-Muñoz M, Vicente-Sánchez A, Garzón J (2013) Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. Antioxid Redox Signal 19:1766–1782CrossRefGoogle Scholar
  47. Sánchez-Blázquez P, Rodríguez-Muñóz M, Garzón J (2014) The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 4:169CrossRefGoogle Scholar
  48. Sánchez-Rodríguez MA, Gómez O, Esteban PF, García-Ovejero D, Molina-Holgado E (2018) The endocannabinoid 2-arachidonoylglycerol regulates oligodendrocyte progenitor cell migration. Biochem Pharmacol 157:180–188.  https://doi.org/10.1016/j.bcp.2018.09.006 CrossRefGoogle Scholar
  49. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477CrossRefGoogle Scholar
  50. Tilleux S, Hermans E (2007) Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 85:2059–2070CrossRefGoogle Scholar
  51. van der Meer P, Ulrich AM, González-Scarano F, Lavi E (2000) Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol 69:192–201CrossRefGoogle Scholar
  52. Verdon B, Zheng J, Nicholson RA, Ganellin CR, Lees G (2000) Stereoselective modulatory actions of oleamide on GABAA receptors and voltage-gated Na+ channels in vitro: a putative endogenous ligand for depressant drug sites in CNS. Br J Pharmacol 129:283–290CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Marisol Maya-López
    • 1
  • Leonardo C. Rubio-López
    • 1
    • 2
  • Ivana V. Rodríguez-Alvarez
    • 1
    • 3
  • Julián Orduño-Piceno
    • 1
    • 3
  • Yuliza Flores-Valdivia
    • 1
    • 2
  • Aline Colonnello
    • 1
    • 2
  • Edgar Rangel-López
    • 1
  • Isaac Túnez
    • 4
    • 5
  • Oscar Prospéro-García
    • 6
  • Abel Santamaría
    • 1
    Email author
  1. 1.Laboratorio de Aminoácidos ExcitadoresInstituto Nacional de Neurología y Neurocirugía, S.S.A.Mexico CityMexico
  2. 2.Facultad de MedicinaUniversidad Autónoma de SinaloaCuliacánMexico
  3. 3.Facultad de CienciasUniversidad Nacional Autónoma de MéxicoMexico CityMexico
  4. 4.Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y EnfermeríaUniversidad de CórdobaCordobaSpain
  5. 5.Instituto Maimonides de Investigación Biomédica de Códoba (IMIBIC) & Red Española de Excelencia de Estimulación Cerebral (REDESTIM)CordobaSpain
  6. 6.Laboratorio de Cannabinoides, Departamento de Fisiología, Facultad de MedicinaUniversidad Nacional Autónoma de MéxicoMexico CityMexico

Personalised recommendations